1. Home
  2. OI vs BEAM Comparison

OI vs BEAM Comparison

Compare OI & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo O-I Glass Inc.

OI

O-I Glass Inc.

HOLD

Current Price

$15.40

Market Cap

2.3B

ML Signal

HOLD

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

HOLD

Current Price

$34.27

Market Cap

2.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OI
BEAM
Founded
1903
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Containers/Packaging
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
2.8B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
OI
BEAM
Price
$15.40
$34.27
Analyst Decision
Buy
Buy
Analyst Count
7
14
Target Price
$17.43
$46.00
AVG Volume (30 Days)
2.0M
1.8M
Earning Date
02-10-2026
02-24-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$6,455,000,000.00
$55,701,000.00
Revenue This Year
$1.39
N/A
Revenue Next Year
$1.60
$26.52
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.23
$13.53
52 Week High
$16.04
$36.44

Technical Indicators

Market Signals
Indicator
OI
BEAM
Relative Strength Index (RSI) 55.00 64.04
Support Level $14.78 $29.80
Resistance Level $16.03 $36.18
Average True Range (ATR) 0.48 2.67
MACD -0.09 0.19
Stochastic Oscillator 50.39 73.70

Price Performance

Historical Comparison
OI
BEAM

About OI O-I Glass Inc.

O-I Glass is the world's largest manufacturer of glass bottles; 70% of its revenue comes from outside the United States. O-I has a leading position in key markets such as Europe, North America, and Brazil. Beer is the primary end market for O-I's glass bottles, which are also used for wine, soda, spirits, condiments, and food. O-I is looking to maintain or expand its dominant positions in Europe, North America, and South America.

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

Share on Social Networks: